Bioventus (NYSE:BVS) Earns Outperform Rating from Analysts at Barrington Research

Barrington Research started coverage on shares of Bioventus (NYSE:BVS) in a research note published on Monday, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $13.00 price target on the stock.

Bioventus Trading Up 0.1%

NYSE BVS opened at $8.08 on Monday. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85. The stock’s 50-day simple moving average is $7.74 and its two-hundred day simple moving average is $7.29. Bioventus has a twelve month low of $5.81 and a twelve month high of $11.25. The company has a market capitalization of $668.73 million, a price-to-earnings ratio of -13.25 and a beta of 0.80.

Insider Buying and Selling

In other Bioventus news, Director Guy P. Nohra sold 10,000 shares of Bioventus stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $7.57, for a total transaction of $75,700.00. Following the transaction, the director directly owned 116,610 shares of the company’s stock, valued at approximately $882,737.70. This trade represents a 7.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 33.00% of the stock is owned by insiders.

Institutional Trading of Bioventus

Several institutional investors have recently added to or reduced their stakes in BVS. Anderson Financial Strategies LLC purchased a new position in shares of Bioventus in the third quarter worth $901,000. Campbell & CO Investment Adviser LLC bought a new stake in Bioventus in the 2nd quarter worth $449,000. Allspring Global Investments Holdings LLC grew its holdings in Bioventus by 79.4% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 66,067 shares of the company’s stock worth $437,000 after acquiring an additional 29,238 shares during the last quarter. Segall Bryant & Hamill LLC increased its position in shares of Bioventus by 468.9% in the second quarter. Segall Bryant & Hamill LLC now owns 281,849 shares of the company’s stock valued at $1,866,000 after acquiring an additional 232,302 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Bioventus by 13.1% during the second quarter. Geode Capital Management LLC now owns 1,054,903 shares of the company’s stock valued at $6,984,000 after acquiring an additional 122,137 shares during the last quarter. 62.94% of the stock is currently owned by hedge funds and other institutional investors.

About Bioventus

Bioventus, Inc (NYSE: BVS) is a global medical technology company focused on providing innovative therapeutic solutions to enhance patient care in musculoskeletal health. The company develops, manufactures, and markets a range of products designed to promote bone healing, support joint health, and relieve pain non-invasively. Bioventus leverages biologic and biophysical approaches to deliver effective therapies that aim to accelerate recovery times and improve overall patient outcomes.

Bioventus’s product portfolio includes its flagship EXOGEN® Bone Healing System, an ultrasound-based device indicated for non-union fractures and fracture healing enhancement.